Currently out of the existing stock ratings of Kristen Kluska, 154 are a BUY (91.12%), 15 are a HOLD (8.88%).

Kristen Kluska

Work Performance Price Targets & Ratings Chart

Analyst Kristen Kluska, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 38.88% that have a potential upside of 40.28% achieved within 101 days.

Kristen Kluska’s has documented 330 price targets and ratings displayed on 29 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on TSHA, Taysha Gene Therapies at 14-Nov-2024.

Wall Street Analyst Kristen Kluska

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/3/2021. The price target of $4 was fulfilled within 2 days with a profit of $1.19 (42.35%) receiving and performance score of 211.74.

Average potential price target upside

of $22.29 (24.8%) on SRPT (SAREPTA THERAPEUTICS).
of $28.2 (49.85%) on GLMD (GALMED PHARMACEUTICALS LTD).
of $16.53 (59.18%) on PTCT (PTC THERAPEUTICS).

CLDX Celldex Therapeutics HTBX Heat Biologics . MBIO Mustang Bio OCGN Ocugen PTE Polarityte RIGL Rigel Pharmaceuticals OCUP Ocuphire Pharma ADMA ADMA Biologics BTX Brooklyn Immunotherapeutics ETNB 89bio FOLD Amicus Therapeutics ABEO Abeona Therapeutics ETN Eaton PLC SRPT Sarepta Therapeutics AGTC Applied Genetic DRRX Durect EVLO Evelo Biosciences MREO Mereo BioPharma Group PLC ADR OTLK OUTLOOK THERAPEUTICS INC SELB Selecta Biosciences TSHA Taysha Gene Therapies XFOR X4 Pharmaceuticals CBAY Cymabay Therapeu GLMD Galmed Pharmaceuticals Ltd HUMA Humacyte IBIO Ibio PTCT PTC Therapeutics SLNO Soleno Therapeutics RARE Ultragenyx

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Joseph Pantginis (HC WAINWRIGHT)